F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more. By Reed Abelson and Rebecca Robbins from NYT (New York Times) Health
Read more.